Last reviewed · How we verify
NCT03541486: XACT-PANC-2
A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients
Phase 2 trial testing Ascorbate in Pancreatic Neoplasm. Withdrawn.
31 December 2029
Quick facts
| Lead sponsor | Joseph J. Cullen, MD, FACS |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Start date | 31 December 2025 |
| Primary completion | 31 December 2029 |
| Estimated completion | 31 December 2030 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Ascorbate — full drug profile →
- Gemcitabine (gemcitabine) — full drug profile →
- radiation therapy — full drug profile →
Conditions studied
- Pancreatic Neoplasm — all drugs for Pancreatic Neoplasm →
Sponsor
Joseph J. Cullen, MD, FACS
Who can join
18 and older, any sex, with Pancreatic Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Radiation therapy improves cancer cure rates by killing cancer cells but it also contributes to long-term side effects in cancer survivors by unintentionally damaging normal organs such as the intestine. This research will what side effects patients with cancer experience, if high dose vitamin C helps reduce these side effects, and if high dose vitamin C increases the survival of patients with pancreatic cancer. We will meet with patients during the study to better understand their experience during their cancer treatment. In the long term, our research could provide a new way help cancer survivors avoid many permanent side effects of cancer treatments.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Metabolic Regulation of Redox Balance in Cancer.
Purohit V, Simeone DM, Lyssiotis CA. · · 2019 · cited 79× · PMID 31288436 · DOI 10.3390/cancers11070955 -
Navigating the redox landscape: reactive oxygen species in regulation of cell cycle.
Mackova V, Raudenska M, Polanska HH, Jakubek M, et al · · 2024 · cited 19× · PMID 38972297 · DOI 10.1080/13510002.2024.2371173 -
Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma.
Rebelo R, Polónia B, Santos LL, Vasconcelos MH, et al · · 2021 · cited 19× · PMID 33804613 · DOI 10.3390/ph14030280 -
Are Aspects of Integrative Concepts Helpful to Improve Pancreatic Cancer Therapy?
Oei SL, Schad F. · · 2023 · cited 5× · PMID 36831465 · DOI 10.3390/cancers15041116 -
The therapeutic potential of vitamins A, C, and D in pancreatic cancer.
Piotrowsky A, Burkard M, Schmieder H, Venturelli S, et al · · 2025 · PMID 39850424 · DOI 10.1016/j.heliyon.2024.e41598
Verify or expand the search:
- PubMed search for NCT03541486
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ascorbate
Trials testing the same drug.
- NCT06018896 — Vitamin C to Quality of Life in Patients With Terminal Stage Pancreatic Cancer · Phase 2 · recruiting
- NCT06018883 — Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer · Phase 3 · active not recruiting
- NCT04634227 — Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot) · EARLY_PHASE1 · active not recruiting
- NCT03508726 — High Dose Ascorbate With Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas · Phase 1, PHASE2 · completed
- NCT03602235 — High Dose Ascorbic Acid for Plasma Cell Disorders · Phase 1 · completed
Other recruiting trials for Pancreatic Neoplasm
Currently open trials in the same condition.
- NCT06807437 — Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula · Phase 3 · recruiting
- NCT05687123 — Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors · Phase 1 · recruiting
- NCT06122896 — Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals · EARLY_PHASE1 · recruiting
- NCT06411795 — Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatodu · Phase 2 · recruiting
- NCT05961982 — Evaluation of Endoscopic Ultrasound-Guided Radiofrequency Ablation for the Management of Pancreatic Tumors, ERASE Study · NA · recruiting
Other Joseph J. Cullen, MD, FACS trials
Trials by the same sponsor.
- NCT02905591 — A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC · Phase 2 · active not recruiting
- NCT01752491 — A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03541486 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Joseph J. Cullen, MD, FACS
- Last refreshed: 10 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03541486.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing